US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

ホーム
投資
株式
イギリス
LSE
Biogen Inc (0R1B)
Biogen Inc (0R1B) ニュース

0R1B

Biogen (0R1B)

Biogen Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:0R1B

1

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/01/23	21 : 30	UK Regulatory	FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA	LSE:0R1B	Biogen Inc
2025/01/14	09 : 05	UK Regulatory	FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease	LSE:0R1B	Biogen Inc
2024/11/19	15 : 00	UK Regulatory	Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity	LSE:0R1B	Biogen Inc
2024/11/15	01 : 23	UK Regulatory	Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease	LSE:0R1B	Biogen Inc
2024/10/31	08 : 30	UK Regulatory	Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference	LSE:0R1B	Biogen Inc
2024/10/30	07 : 00	UK Regulatory	Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases	LSE:0R1B	Biogen Inc
2024/10/29	21 : 00	UK Regulatory	Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer	LSE:0R1B	Biogen Inc
2024/10/28	21 : 30	UK Regulatory	Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025	LSE:0R1B	Biogen Inc
2024/10/27	09 : 15	UK Regulatory	Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024	LSE:0R1B	Biogen Inc
2024/10/24	20 : 30	UK Regulatory	Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference	LSE:0R1B	Biogen Inc
2024/10/22	20 : 30	UK Regulatory	Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024	LSE:0R1B	Biogen Inc
2024/10/09	20 : 30	UK Regulatory	Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients	LSE:0R1B	Biogen Inc
2024/10/08	20 : 30	UK Regulatory	New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA	LSE:0R1B	Biogen Inc
2024/09/24	14 : 00	UK Regulatory	UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024	LSE:0R1B	Biogen Inc
2024/09/12	20 : 30	UK Regulatory	Biogen Board Appoints Two New Independent Directors	LSE:0R1B	Biogen Inc
2024/09/04	20 : 30	UK Regulatory	Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA	LSE:0R1B	Biogen Inc
2024/07/31	06 : 15	UK Regulatory	New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC	LSE:0R1B	Biogen Inc
2024/07/30	20 : 30	UK Regulatory	Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease	LSE:0R1B	Biogen Inc
2024/07/26	20 : 20	UK Regulatory	Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union	LSE:0R1B	Biogen Inc
2024/03/06	21 : 30	UK Regulatory	New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy	LSE:0R1B	Biogen Inc
2024/03/05	06 : 15	UK Regulatory	Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting	LSE:0R1B	Biogen Inc
2024/02/23	21 : 00	UK Regulatory	Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP	LSE:0R1B	Biogen Inc
2024/02/13	06 : 06	UK Regulatory	Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia	LSE:0R1B	Biogen Inc
2024/01/31	21 : 30	UK Regulatory	Biogen to Realign Resources for Alzheimer's Disease Franchise	LSE:0R1B	Biogen Inc
2023/08/07	01 : 07	Alliance News	CORRECT: Biogens, Sage Therapeutics postpartum depression drug okayed	LSE:0R1B	Biogen Inc
2023/08/06	22 : 17	Alliance News	Biogens, Sage Therapeutics postpartum depression treatment approved	LSE:0R1B	Biogen Inc
2023/06/09	20 : 12	Alliance News	*Nasdaq halts trading of Biogen stock	LSE:0R1B	Biogen Inc
2020/01/13	23 : 28	Alliance News	Pfizer Could Net USD635 Million As Biogen Acquires Alzheimer's Drug	LSE:0R1B	Biogen Inc

Showing the most relevant articles for your search:LSE:0R1B

1

Energy Select Sector SPDR

American Express

Deutsche Telekom (QX)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約